November 19, 2024
1 min watch
Save
VIDEO: ONL1204 has different approach for treatment of geographic atrophy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this video, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses study results presented at the AAO meeting on ONL1204 from ONL Therapeutics.
“It’s a very different approach, really more of a neuroprotective approach for [geographic atrophy] and that I think is kind of exciting,” Miller said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Miller reports serving as a named inventor on patents and patent applications for ONL Therapeutics; serving as a consultant for ONL Therapeutics and Sumitomo Pharma Co.; serving in an advisory role for Drusolv Therapeutics; and receiving grant support from Lowy Medical Research Institute. Massachusetts Eye and Ear has a proprietary interest in photodynamic therapy and has received financial remuneration related to this technology. Miller reports receiving a share of the same in accordance with institutional guidelines.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.